NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Price Target & More

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) announced its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.94) by $0.03. The specialty pharmaceutical company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. View Paratek Pharmaceuticals' Earnings History.

7 analysts have issued 12 month price targets for Paratek Pharmaceuticals' stock. Their forecasts range from $36.00 to $55.00. On average, they expect Paratek Pharmaceuticals' share price to reach $45.00 in the next year. This suggests a possible upside of 328.6% from the stock's current price. View Analyst Ratings for Paratek Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Paratek Pharmaceuticals include Radius Health (RDUS), Alder Biopharmaceuticals (ALDR), Lexicon Pharmaceuticals (LXRX), Endocyte (ECYT), Zai Lab (ZLAB), Eagle Pharmaceuticals (EGRX), Athenex (ATNX), Tricida (TCDA), Retrophin (RTRX), Esperion Therapeutics (ESPR), Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), Revance Therapeutics (RVNC), Wave Life Sciences (WVE) and Apellis Pharmaceuticals (APLS).

Media stories about PRTK stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 43.72 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRTK stock can currently be purchased for approximately $10.50.

Paratek Pharmaceuticals has a market capitalization of $336.50 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]